- Home
- GAU vs CELC Comparison
GAU vs CELC Comparison
Compare GAU & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAU
- CELC
- Stock Information
- Founded
- GAU 1999
- CELC 2011
- Country
- GAU Canada
- CELC United States
- Employees
- GAU N/A
- CELC 87
- Industry
- GAU
- CELC Medical Specialities
- Sector
- GAU
- CELC Health Care
- Exchange
- GAU Nasdaq
- CELC Nasdaq
- Market Cap
- GAU 342.0M
- CELC 409.7M
- IPO Year
- GAU N/A
- CELC 2017
- Fundamental
- Price
- GAU $1.46
- CELC $13.01
- Analyst Decision
- GAU Strong Buy
- CELC Strong Buy
- Analyst Count
- GAU 1
- CELC 5
- Target Price
- GAU $2.80
- CELC $30.80
- AVG Volume (30 Days)
- GAU 967.1K
- CELC 145.0K
- Earning Date
- GAU 05-14-2025
- CELC 05-14-2025
- Dividend Yield
- GAU N/A
- CELC N/A
- EPS Growth
- GAU N/A
- CELC N/A
- EPS
- GAU N/A
- CELC N/A
- Revenue
- GAU $276,234,000.00
- CELC N/A
- Revenue This Year
- GAU $70.62
- CELC N/A
- Revenue Next Year
- GAU $40.51
- CELC N/A
- P/E Ratio
- GAU N/A
- CELC N/A
- Revenue Growth
- GAU 771.54
- CELC N/A
- 52 Week Low
- GAU $1.00
- CELC $7.58
- 52 Week High
- GAU $2.00
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- GAU 54.44
- CELC 68.76
- Support Level
- GAU $1.31
- CELC $11.57
- Resistance Level
- GAU $1.56
- CELC $12.34
- Average True Range (ATR)
- GAU 0.08
- CELC 0.53
- MACD
- GAU 0.01
- CELC 0.16
- Stochastic Oscillator
- GAU 67.74
- CELC 98.08
About GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.